Form 4: Aveanna Healthcare Holdings Insider Paul R. Vigano Reports Stock Sales Under 10b5-1 Plan

Paul R. Vigano, a director at Aveanna Healthcare Holdings, reported the sale of common stock indirectly held through various entities, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Paul R. Vigano, a director of Aveanna Healthcare Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The reported transactions involve the sale of common stock held indirectly through several entities, including J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, JHW Iliad Holdings LLC, PSA Iliad Holdings LLC, and JHW Iliad Holdings II LLC.
• The sales occurred on March 24 and March 25, 2025, at weighted average prices of $5.63 and $5.64 per share, respectively.
• These sales were executed automatically under a Rule 10b5-1 trading plan adopted on December 13, 2024.
• Vigano disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
• Vigano has authorized Robert M. Williams and David Zatlukal to file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on current, non-public information. The healthcare industry is subject to various regulations and market dynamics, and insider transactions are always scrutinized by investors.

Comparison to Industry Standards

• Comparing these transactions to other insider sales within the healthcare sector would require analyzing similar Form 4 filings for companies like UnitedHealth Group (UNH), CVS Health (CVS), or HCA Healthcare (HCA).
• The size and frequency of the sales can be benchmarked against typical insider trading patterns in comparable companies to assess whether they are routine or potentially indicative of a larger trend.
• The use of a 10b5-1 plan is a common practice among corporate insiders to avoid accusations of trading on non-public information, aligning with standard corporate governance practices.

Stakeholder Impact

• The sales could have a minor negative impact on shareholder sentiment if misinterpreted as a lack of confidence by the director, although the 10b5-1 plan mitigates this concern.
• Employees and other stakeholders are unlikely to be directly affected by these transactions.

Key Dates

Keywords

Form 4, insider trading, Rule 10b5-1, stock sales, beneficial ownership, Aveanna Healthcare Holdings, AVAH, Paul R. Vigano